Navigation Links
Pharmaceutical Water Markets, the Economic Crunch Creates New Opportunities in Southern and Eastern Europe
Date:12/8/2008

LONDON, Dec. 8 /PRNewswire/ -- High Purity Water is a critical ingredient in the manufacturing process of life saving drugs. The continuing demand for high quality water (HQW) is the single biggest driver for the growth of the water treatment systems market segment in the pharmaceutical sector. Frost & Sullivan's European Environment Research Analyst, Karthikeyan Ravikumar, foresees "that the water and wastewater management market in the European pharmaceutical industry has exciting opportunities to offer particularly in the water treatment segment with the overall market experiencing high growth rates".

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

With Europe as the second largest pharmaceutical manufacturing markets around it has emerged as a very lucrative high value opportunity to stake holders in the water industry. Some of the leading players have made significant investments on research and development as well as positioning themselves as providers of specialist solutions for the pharmaceutical sectors. These investments are channelled to enhance innovative water and wastewater treatment solutions, test and improve existing technologies to meet the current and expected changes to the European Pharmacopoeia's water standards.

The European pharmaceutical market is expected to showcase an annual growth rate of around 8-10 percent in the coming years and this is expected to reflect in a steady increase in the need for effective and efficient water as well as wastewater treatment technologies and services.

Furthermore, the current economic situation may open new and interesting opportunities in Southern and Eastern Europe. Karthikeyan Ravikumar reports that "with the economic slowdown triggered from the United States of America spreading to other regions of the globe, the pharmaceutical industries in Europe may take a cautious stand of wait and watch policy". This cautious stand could have an impact on the water and wastewater management needs of pharmaceutical industries. In this period of economic crunch, pharmaceutical companies have indicated an increased interest in moving South and East of Europe, to tap into relatively low production and operational costs.

Frost & Sullivan is in the process of completing a Snapshot Study on Water & Wastewater Treatment in the European Pharmaceutical Industry. In the meantime, if you are interested in receiving more information on the European Water & Wastewater Treatment Markets, please send an e-mail to Chiara Carella - Corporate Communications at chiara.carella@frost.com with your full name, company name, title, telephone number, e-mail address, city and country. Upon receipt of the above information, an overview will be sent to you by e-mail.

All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

    Contacts:
    Chiara Carella
    Corporate Communications - Europe
    P: +44 (0) 20 7343 8314
    E: chiara.carella@frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ISTA Pharmaceuticals to Participate at the RBC Capital Markets Healthcare Conference
2. Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas
3. Memory Pharmaceuticals Receives NASDAQ Decisions
4. MAP Pharmaceuticals to Present at the 2008 RBC Capital Markets Healthcare Conference
5. Best Practice Database Adds Research Highlighting Effective Tactics of Sales Force and Manufacturing Groups in the Pharmaceutical Industry
6. The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders
7. Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference
8. Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel
9. China West II Files Suit Against Genesis Pharmaceuticals and Capital Research Group Inc, Announces Conference Call Details
10. Watson Pharmaceuticals Receives FDA Final Approval for Generic Wellbutrin XL(R) 150 mg
11. Idenix Pharmaceuticals to Present at the PiperJaffray 20th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... "Add realistic flares and light leaks to your ... clip to clip with high quality 4K lens flare footage," said Christina Austin - ... flares filmed on the RED Dragon. Utilizing the Dragon Sensor, TransFlare 4K Jewel lens ...
(Date:12/5/2016)... , ... December 05, 2016 , ... What: Shriners Hospitals ... the North Pole to our patients – using a video monitor and web-enabled camera. ... hospital will transform the Auditorium into a Christmas Wonderland, which is where the video ...
(Date:12/5/2016)... ... 05, 2016 , ... Edward Buckingham MD , and ... of the newest Sciton laser in January 2017. The Halo is the first ... ablative wavelengths for exceptional results. Outperforming more traditional lasers, the innovative Halo automatically ...
(Date:12/5/2016)... ... , ... For many years, Andrew G. Zubinas has accumulated over ... of the Lithuanian language and its poetry inspired him in writing “ ... explores all aspects of a living, breathing forest where nothing ever stays the same. ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... relationship-marketing firm, announced today that nominations will be accepted from December 5, ... Central Awards. , Awards include the Information Security Executive® of the Year, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 ... today announced preliminary safety and efficacy data from ... oral selective MDM2 inhibitor, suggesting that DS-3032 may ... relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic ... part of the phase 1 study of DS-3032 were ...
(Date:12/5/2016)... , Dec. 5, 2016 Eisai Inc. announced ... the 2016 Annual Meeting of the American Epilepsy Society ... is indicated as an adjunctive therapy for the treatment ... generalized seizures and primary generalized tonic-clonic seizures (PGTC) in ... and older. Please see Important Safety Information for FYCOMPA, ...
(Date:12/5/2016)... BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... candidates, presents positive Phase 2a correlative data, as well as ... at the ongoing 58th American Society of Hematology (ASH) Annual ... . ... As previously announced, in ...
Breaking Medicine Technology: